Which has better valuation and earnings, HNGE or PGNY?

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86M 12.57 -$528.26M $1.28 71.56 Progyny $1.29B 1.61 $58.52M $0.92 29.48

Is HNGE or PGNY more profitable?

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Hinge Health 15.15% 51.60% 14.16% Progyny 6.00% 15.98% 10.65%

Does the media prefer HNGE or PGNY?

In the previous week, Progyny had 5 more articles in the media than Hinge Health. MarketBeat recorded 8 mentions for Progyny and 3 mentions for Hinge Health. Hinge Health's average media sentiment score of 1.23 beat Progyny's score of 1.23 indicating that Hinge Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hinge Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CHE or PGNY?

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.68 $265.24M $19.91 26.02 Progyny $1.29B 1.61 $58.52M $0.92 29.48

Is CHE or PGNY more profitable?

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Progyny 6.00% 15.98% 10.65%

Does the media prefer CHE or PGNY?

In the previous week, Chemed had 1 more articles in the media than Progyny. MarketBeat recorded 9 mentions for Chemed and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat Chemed's score of 0.90 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HIMS or PGNY?

In the previous week, Hims & Hers Health had 30 more articles in the media than Progyny. MarketBeat recorded 38 mentions for Hims & Hers Health and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat Hims & Hers Health's score of 0.07 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 6 Very Positive mention(s) 3 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PGNY or RDNT?

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.61 $58.52M $0.92 29.48 RadNet $2.04B 2.73 -$18.65M -$0.27 N/A

Is PGNY or RDNT more profitable?

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% RadNet -0.93% 2.61% 0.91%

Does the media favor PGNY or RDNT?

In the previous week, RadNet had 1 more articles in the media than Progyny. MarketBeat recorded 9 mentions for RadNet and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat RadNet's score of 0.90 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RadNet 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LFST or PGNY?

In the previous week, LifeStance Health Group had 8 more articles in the media than Progyny. MarketBeat recorded 16 mentions for LifeStance Health Group and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat LifeStance Health Group's score of 0.94 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$27.12 -0.03 (-0.11%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$27.05 -0.07 (-0.25%)

As of 07:21 AM Eastern

Compare

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

Should you buy Progyny stock or one of its competitors? Progyny's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Progyny compare to Hinge Health?

Hinge Health (NYSE:HNGE) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Progyny had 5 more articles in the media than Hinge Health. MarketBeat recorded 8 mentions for Progyny and 3 mentions for Hinge Health. Hinge Health's average media sentiment score of 1.23 beat Progyny's score of 1.23 indicating that Hinge Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hinge Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hinge Health has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Progyny has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hinge Health	$587.86M	12.57	-$528.26M	$1.28	71.56
Progyny	$1.29B	1.61	$58.52M	$0.92	29.48

Hinge Health currently has a consensus price target of $101.93, indicating a potential upside of 11.28%. Progyny has a consensus price target of $34.36, indicating a potential upside of 26.71%. Given Progyny's stronger consensus rating and higher probable upside, analysts clearly believe Progyny is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hinge Health	15.15%	51.60%	14.16%
Progyny	6.00%	15.98%	10.65%

94.9% of Progyny shares are owned by institutional investors. 18.9% of Hinge Health shares are owned by insiders. Comparatively, 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Hinge Health beats Progyny on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to Chemed?

Chemed (NYSE:CHE) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Progyny	6.00%	15.98%	10.65%

95.9% of Chemed shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 3.3% of Chemed shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.68	$265.24M	$19.91	26.02
Progyny	$1.29B	1.61	$58.52M	$0.92	29.48

Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Progyny has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Chemed currently has a consensus price target of $530.75, indicating a potential upside of 2.44%. Progyny has a consensus price target of $34.36, indicating a potential upside of 26.71%. Given Progyny's stronger consensus rating and higher possible upside, analysts plainly believe Progyny is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Chemed had 1 more articles in the media than Progyny. MarketBeat recorded 9 mentions for Chemed and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat Chemed's score of 0.90 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats Progyny on 9 of the 17 factors compared between the two stocks.

How does Progyny compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Hims & Hers Health currently has a consensus price target of $32.50, suggesting a potential upside of 16.87%. Progyny has a consensus price target of $34.36, suggesting a potential upside of 26.71%. Given Progyny's stronger consensus rating and higher probable upside, analysts clearly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Progyny has a net margin of 6.00% compared to Hims & Hers Health's net margin of -5.51%. Progyny's return on equity of 15.98% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
Progyny	6.00%	15.98%	10.65%

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.76	$128.37M	-$0.63	N/A
Progyny	$1.29B	1.61	$58.52M	$0.92	29.48

In the previous week, Hims & Hers Health had 30 more articles in the media than Progyny. MarketBeat recorded 38 mentions for Hims & Hers Health and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat Hims & Hers Health's score of 0.07 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	6 Very Positive mention(s)	3 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.42, meaning that its stock price is 142% more volatile than the broader market. Comparatively, Progyny has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Comparatively, 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Progyny beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to RadNet?

Progyny (NASDAQ:PGNY) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Progyny presently has a consensus target price of $34.36, suggesting a potential upside of 26.71%. RadNet has a consensus target price of $90.00, suggesting a potential upside of 26.99%. Given RadNet's stronger consensus rating and higher possible upside, analysts clearly believe RadNet is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.61	$58.52M	$0.92	29.48
RadNet	$2.04B	2.73	-$18.65M	-$0.27	N/A

94.9% of Progyny shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
RadNet	-0.93%	2.61%	0.91%

Progyny has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, RadNet has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

In the previous week, RadNet had 1 more articles in the media than Progyny. MarketBeat recorded 9 mentions for RadNet and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat RadNet's score of 0.90 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Progyny beats RadNet on 10 of the 17 factors compared between the two stocks.

How does Progyny compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

85.5% of LifeStance Health Group shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 3.5% of LifeStance Health Group shares are held by insiders. Comparatively, 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Progyny has a net margin of 6.00% compared to LifeStance Health Group's net margin of 3.19%. Progyny's return on equity of 15.98% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	3.19%	3.39%	2.33%
Progyny	6.00%	15.98%	10.65%

LifeStance Health Group currently has a consensus target price of $12.63, suggesting a potential upside of 0.04%. Progyny has a consensus target price of $34.36, suggesting a potential upside of 26.71%. Given Progyny's stronger consensus rating and higher possible upside, analysts plainly believe Progyny is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, LifeStance Health Group had 8 more articles in the media than Progyny. MarketBeat recorded 16 mentions for LifeStance Health Group and 8 mentions for Progyny. Progyny's average media sentiment score of 1.23 beat LifeStance Health Group's score of 0.94 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeStance Health Group has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Progyny has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Progyny has lower revenue, but higher earnings than LifeStance Health Group. Progyny is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	3.44	$9.66M	$0.13	97.08
Progyny	$1.29B	1.61	$58.52M	$0.92	29.48

Summary

Progyny beats LifeStance Health Group on 11 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.08B	$9.94B	$7.22B	$12.88B
Dividend Yield	N/A	2.60%	2.55%	9.95%
P/E Ratio	29.48	34.04	271.78	25.29
Price / Sales	1.61	4.92	712.57	118.14
Price / Cash	36.88	124.77	77.55	52.32
Price / Book	4.53	5.32	10.50	6.26
Net Income	$58.52M	$313.25M	$3.48B	$357.86M
7 Day Performance	1.92%	-0.74%	-1.17%	-0.59%
1 Month Performance	-2.62%	-1.20%	2.00%	-1.07%
1 Year Performance	19.84%	16.48%	21.90%	11.31%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.2118 of 5 stars	$27.12 -0.1%	$34.36 +26.7%	+18.1%	$2.08B	$1.29B	29.48	310	Positive News Analyst Forecast
HNGE Hinge Health	3.846 of 5 stars	$92.27 +5.6%	$100.57 +9.0%	+59.3%	$7.05B	$587.86M	72.09	1,437	Analyst Forecast
CHE Chemed	3.5523 of 5 stars	$518.26 -1.0%	$530.75 +2.4%	+11.9%	$6.84B	$2.53B	26.03	15,811
HIMS Hims & Hers Health	2.3908 of 5 stars	$29.56 +2.5%	$32.50 +9.9%	-41.7%	$6.73B	$2.35B	N/A	2,442	Trending News
RDNT RadNet	4.1722 of 5 stars	$75.82 +1.6%	$90.00 +18.7%	-3.0%	$5.87B	$2.04B	N/A	11,264

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Progyny compare to Hinge Health?

Summary

How does Progyny compare to Chemed?

Summary

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Progyny compare to Hinge Health?

Does the media prefer HNGE or PGNY?

Which has more risk & volatility, HNGE or PGNY?

Which has better valuation and earnings, HNGE or PGNY?

Do analysts recommend HNGE or PGNY?

Is HNGE or PGNY more profitable?

Do insiders and institutionals have more ownership in HNGE or PGNY?

Summary

How does Progyny compare to Chemed?

Is CHE or PGNY more profitable?

Do institutionals & insiders have more ownership in CHE or PGNY?

Which has higher earnings & valuation, CHE or PGNY?

Which has more volatility & risk, CHE or PGNY?

Do analysts recommend CHE or PGNY?

Does the media prefer CHE or PGNY?

Summary

How does Progyny compare to Hims & Hers Health?

Do analysts rate HIMS or PGNY?

Is HIMS or PGNY more profitable?

Which has higher earnings & valuation, HIMS or PGNY?

Does the media refer more to HIMS or PGNY?

Which has more risk & volatility, HIMS or PGNY?

Do insiders & institutionals hold more shares of HIMS or PGNY?

Summary

How does Progyny compare to RadNet?

Do analysts prefer PGNY or RDNT?

Which has better earnings & valuation, PGNY or RDNT?

Do insiders & institutionals believe in PGNY or RDNT?

Is PGNY or RDNT more profitable?

Which has more volatility & risk, PGNY or RDNT?

Does the media favor PGNY or RDNT?

Summary

How does Progyny compare to LifeStance Health Group?

Do insiders and institutionals hold more shares of LFST or PGNY?

Is LFST or PGNY more profitable?

Do analysts recommend LFST or PGNY?

Does the media refer more to LFST or PGNY?

Which has more volatility & risk, LFST or PGNY?

Which has preferable earnings and valuation, LFST or PGNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools